General (87) Financials (10) Partnerships (4) Acquisitions (2) New Products (2)
Pharma and Biotech (29) Consumer Care (18) Bioscience (13) Corporate (9)
2019 (90)
English (90)
2019X
EnglishX
Showing 1‐20 of 90
results per page
19 Dec 2019
Lonza and Allevi Collaborate to Advance 3D Bioprinting
Collaboration brings technology and consumables together for bioprinting for research applications.Lonza brings a broad range of high-quality...
19 Dec 2019
Invitation to Lonza’s Full-Year Results 2019 Investor & Analyst Conference
Lonza is pleased to invite you to our Full-Year Results 2019 Conference in Zurich, Switzerland.DateTuesday, 21 January 2020LocationSIX...
26 Nov 2019
Lonza and DiNAQOR AG Announce Strategic Collaboration to Advance Gene Therapy Programs for Patients with Monogenic Cardiomyopathies
Strategic collaboration to focus on DiNAQOR’s adeno-associated virus gene therapy production systemCompanies to partner on gene therapy process and...
20 Nov 2019
Navrogen Inc. and Lonza Sign Agreement to Use Lonza’s GS Gene Expression System ® for Navrogen’s Anti-HIO Targeting Agents
Navrogen developing therapies to target Humoral Immuno-Oncology (HIO) factors and reverse inhibitory activity against antibody-based...
13 Nov 2019
Lonza’s New eCHO™ Basal Medium and Feed Facilitates Late-Stage Cell Viability and a Consistent Yield of High Integrity Proteins
Lonza has launched a new basal and feed medium, specifically developed to drive significant viability and integrity enhancements in protein...
12 Nov 2019
Board Announcement
Basel, Switzerland, 12 November 2019 – – Lonza announced today that Marc Funk, CEO, will leave the Company for personal reasons. The Board of...
05 Nov 2019
Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Delivery Network in Cell & Gene Therapy
Cryoport as a preferred partner for Lonza in the transport and delivery of patient tissues on a global basisPartnership incorporates Cryoport’s...
04 Nov 2019
Lonza Launches Vcaps® Plus White Opal®, A High-Performance, Semi-Opaque, Plant-Based Capsule at CPhI Worldwide 2019
•  Vcaps® Plus White Opal® capsule is Lonza’s first commercially-available titanium dioxide-free semi-opaque capsule for food supplements •  The...
28 Oct 2019
Lonza to Host New Webinar – “Paper to EBR in 9 Months: How a Strong Collaboration Leads to Project Success”
Free Lonza webinar to discuss the benefits of a collaborative approach to implementing an Electronic Batch Record PlatformBasel, Switzerland, 28...
22 Oct 2019
Lonza Announces Short, Routine Shutdown of Niacinamide Plant in Nansha (CN) for Maintenance
Basel, Switzerland, 22 October 2019 – Lonza today announced that it will shut down its production of Niacinamide (vitamin B3) in Nansha (CN) in...
16 Oct 2019
Mesoblast and Lonza Enter into Agreement for Commercial Manufacture of Mesoblast’s Potential First United States Allogeneic Therapy
Quote from Alberto Santagostino, SVP Head of Cell & Gene Technologies, Lonza:“Mesoblast is a true trailblazer, leading the way in developing...
16 Oct 2019
Lonza Strengthens Sports Nutrition Portfolio with the Launch of Vegan MuscleGuard ™ Formulation
Shane Durkee, Vice President of Platform Innovation Consumer Health & Nutrition at Lonza:“At Lonza, we continue to push the boundaries of...
14 Oct 2019
Lonza’s Ibex™ Solutions to Support Genmab’s Growing Clinical Portfolio
Lonza’s Ibex™ Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 monthsLonza’s Ibex™ Develop will enable...
10 Oct 2019
Lonza to Highlight Innovative Capsugel® Capsule Technologies at CPhI Worldwide 2019
Capsule Delivery Solutions, part of Lonza Pharma & Biotech, will showcase its portfolio of innovative products and services at the annual CPhI...
08 Oct 2019
Prevail Therapeutics and Lonza Establish Strategic Collaboration to Develop and Manufacture Prevail's Novel AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases
Strategic collaboration focuses on baculovirus/Sf9 expression system for Prevail's pipeline of novel AAV9-based gene therapy programs for patients...
03 Oct 2019
Lonza’s MODA-ES TM Platform helps Nephron Pharmaceuticals move from paper to an EBR in nine months – Case study to be presented at 2019 ISPE Annual Meeting
Lonza has partnered with Nephron Pharmaceuticals Corporation to implement Lonza’s next-generation MODA-ESTM EBR Platform to streamline...
01 Oct 2019
Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates
Agreement covers manufacturing of clinical supply for Cellectis’ UCART pipelineManufacturing to take place at Lonza’s GMP site in Geleen,...
01 Oct 2019
Lonza to Host New Webinar – “Cell Culture Media: Why Go Serum-Free?”
Free Lonza webinar to discuss the benefits of working with serum-free cell culture media and provide guidance on how to get the best resultsBasel,...
27 Sep 2019
Lonza Lights Up Las Vegas with Science-Backed Ingredients and Formulations at SupplySide West 2019
Morristown, NJ (USA), 27 September 2019 - Lonza will be showcasing its comprehensive range of scientifically-backed ingredients and formulations...
23 Sep 2019
Lonza Launches Joint Health Consumer Education Campaign with New York Photography Exhibition
•  Lonza announces the launch of a high-impact consumer education initiative, aimed at driving joint health awareness among adults•  The Lifestyle...
1 2 3 4 ... 5 >